Pyoderma gangrenosum
Pyoderma gangrenosum ke lefu le sa tloaelehang la ho ruruha letlalo moo pustules kapa maqhutsu a bohloko a fetohang liso tse ntseng li hola butle-butle. Pyoderma gangrenosum ha e tšoaetsane. Kalafo e ka kenyelletsa corticosteroids, cyclosporin, kapa li-antibodies tse fapaneng tsa monoclonal. Leha e ka ama batho ba lilemo life kapa life, hangata e ama batho ba lilemong tsa bo-40 le bo-50.
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
Leotong la motho ea nang le lefu la ho ruruha ha liso.
References
Pyoderma gangrenosum ke boemo bo sa tloaelehang ba letlalo bo bakang liso tse bohloko tse nang le likarolo tse khubelu kapa tse pherese. E khetholloa e le lefu la ho ruruha 'me ke karolo ea sehlopha se bitsoang neutrophilic dermatoses. Sesosa sa pyoderma gangrenosum se rarahane, se kenyelletsa mathata a ts'ireletso ea tlhaho le e feto-fetohang ho batho ba nang le liphatsa tsa lefutso. Haufinyane tjena, bafuputsi ba tsepamisitse maikutlo ho follicule ea moriri e le monyetla oa ho qala lefu lena.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum ke boemo bo sa tloaelehang ba letlalo bo bakang liso tse bohloko haholo. Le hoja re sa utloisise ka botlalo sesosa sa eona, rea tseba hore e kenyelletsa tšebetso e eketsehileng ea lisele tse itseng tsa 'mele. Ho phekola lefu lena ha ho ntse ho le bonolo. Re na le lithethefatsi tse sa tšoaneng tse hatellang tsamaiso ea ’mele ea ho itšireletsa mafung kapa tse fetolang tšebetso ea eona. Ntle le tsena, re shebana hape le ho phekola maqeba le ho laola bohloko. Corticosteroids le cyclosporine hangata ke khetho ea pele bakeng sa kalafo, empa morao tjena, ho bile le lipatlisiso tse ngata mabapi le ho sebelisa litlhare tsa biologic joalo ka TNF-α inhibitors. Li-biologics tsena li ntse li ratoa haholo, haholo ho bakuli ba nang le maemo a mang a ho ruruha, 'me li ntse li sebelisoa pejana ts'ebetsong ea lefu lena.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
